November 2017 Vol 8, No 11
In this issue of the Journal of Oncology Navigation & Survivorship (JONS), we are proud to present the evidence-based research abstracts that have been accepted to the Eighth Annual Navigation & Survivorship Conference of the Academy of Oncology Nurse & Patient Navigators (AONN+).
Heidi Eve-Cahoon, MSN, RN, CNP, CBCN, Sharon Lieb Inzetta, RN, MS, CBCN, CN-BN, ONN-CG, Melanie Lynch, MD, FACS, Laura Musarra, BS, MBA
Today there are ever-increasing challenges surrounding breast cancer care. The ongoing disparities in delivering cancer care continue to impact our nation as a whole, and, more importantly, for both patients and providers in our local communities.
Nora J. Barrett, BSN, RN, OCN, ONN-CG, Kristi C. Garrison, MS, CHES, CHW, OPN-CG, Stacey L. Webb, MPA-HCA, BSN, RN, ONN-CG
Currently, pancreatic cancer (PC) is the fourth leading cause of cancer mortality in the United States. However, with the lack of early detection tests and treatment options, it is estimated that PC may move to the second leading cause of cancer death in the United States by 2020 or even earlier.
The tumor board, or multidisciplinary cancer conference (MCC), is the foundation of high-value multidisciplinary oncology care through coordinating teams of specialists.
According to Morgan, “Lung Cancer is the leading cause of cancer-related death in the United States, claiming more lives than colon, breast, and prostate cancer combined.”
The multidisciplinary cancer conference (MCC) plays an integral role in optimizing patient outcomes in today’s increasingly complex world of cancer care.
Accessing chimeric antigen receptor (CAR) T-cell clinical trials for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL) is challenging for pediatric patients who have experienced a relapse of B-cell ALL or have been refractory to standard therapy.
The Johns Hopkins Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Sibley Memorial Hospital, performs more than 500 surgeries annually.
The Cancer Support Community (CSC) has designed a patient/provider discussion tool for patients with chronic myeloid leukemia (CML).
Each woman’s risk of developing breast cancer is different and depends on her lifestyle, family health history, and other factors. The American Cancer Society considers women who have a lifetime risk assessment of 20% or greater to be at high risk for breast cancer.
Patients with advanced neuroendocrine tumors may develop carcinoid syndrome, a rare condition characterized by debilitating symptoms, including diarrhea, flushing, and valvular heart damage, that can greatly affect patient social and physical functioning.
Keith Argenbright, MD, Emily Berry, MSPH, Stephanie Mamantov, ACSM/ACS, Tracy Mazour, RN, MSN, OCN, Aurelio Rodriguez, Lisa Ross, BS, ACSM/ACS
Exercise is a multipurpose tool that can be used to help cancer survivors improve their quality of life (QOL) across the cancer continuum.
JaLisa Boyd, MS, BSN, RN, Emily Gentry, BSN, RN, HON-ONN-CG, OCN, Katie Narvarte, LMSW, OSW-C, OPN-CG
Sarah Cannon Cancer Institute, the Oncology Service line for Medical City Healthcare in the Dallas/Fort Worth, Texas area, has a team of 13 disease-suite oncology nurse navigators and 2 survivorship navigators.
The authors present their findings from a study testing the effects of an early intervention by the Breast Cancer Navigator on distress.
Frank Riessman’s Helper Theory (1965) posits that peer support networks can be powerful tools to extend care delivery—benefiting both the giver and receiver of informal care.
Research has consistently found that caregivers for people with cancer report distress; however, it is not clear whether recent improvements in the treatment of chronic myelogenous leukemia (CML) have reduced caregiver burden.
The Institute of Medicine (IOM) 2013 report recommends that supportive oncology care start at cancer diagnosis; the Commission on Cancer (CoC) Standard 3.2 requires distress screening and indicated action.
The burden of cancer has largely focused on the patient. However, caregivers also experience considerable burden.
Animal Assisted Therapy (AAT) is a supportive therapy that is currently underutilized in the outpatient oncology setting.
Carolyn Allsen, BSN, RN, OCN, ONN-CG, Sylvia Brown, MS, RN, OCN, CNL, ONN-CG, Sandra Miller, MHSM, RN, NE-BC
Since the inception of the oncology nurse navigator (ONN) program at Memorial Hermann Hospital System (MHHS) in 2009, the role of the ONN was vastly misunderstood, and the overall potential benefits for the hospital and patient were undefined.
The Academy of Oncology Nurse & Patient Navigators conducted a 1.5-day live conference April 27-29, 2017, in Phoenix, AZ.
Jackie Gonzalez, DNP, MBA, ARNP, NEA-BC, FANN, Lilliam Rimblas, RN, BSN, CPHON, Peggy Townsend, MSN, RN, CPON
Navigation is defined as the “guiding force promoting the timely movement of the patient through a complex system of care.”
Alyssa Pauls, RN, BSN, OCN, Kathleen Sevedge, RN, MA, AOCN, Cynthia Smith, RN, BSN, OCN, MA, Laura Beaupre, RN, BSN, OCN, CN-BN, Maritza Chicas, RN, BSN, OCN
Multidisciplinary care is recognized as a sign of quality cancer care according to several organizations, including the American Society of Clinical Oncology, the Institute of Medicine, the National Cancer Institute Community Cancer Centers Program (NCCCP), and the Oncology Roundtable.
The number of cancer survivors is increasing because of advances in detection and treatment.
Transitions in care require well-managed timing and sequencing of events across specialties.
As people with a history of cancer are living longer and surviving their cancer, today it is estimated that there are 14 million cancer survivors in the United States.
Andrew Bai, MS, Ruben A. Mesa, MD, FACP, Dilan Paranagama, PhD, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, PhD
The MPNs myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are associated with a variety of burdensome symptoms (BMC Cancer. 2016;16:167) and reduced survival compared with the general population (PLOS One. 2014;9:e90299).
Patient navigation has been shown to improve patient engagement and participation in clinical trials and reduce barriers to cancer care.
Sarah Cannon’s San Antonio market was seeking a way to effectively improve key quality and operational navigation metrics on their monthly Navigation Market Scorecard.
Carolyn Allsen, BSN, RN, OCN, ONN-CG, Sylvia Brown, MS, RN, OCN, CNL, ONN-CG, Sandra Miller, MHSM, RN, NE-BC
The American Cancer Society acknowledged an estimated 1,688,780 new cancer diagnoses by the end of 2017.
Work is central for most adults in the United States, including women with breast cancer.
Cancer patients must juggle doctor appointments; combat treatment side effects, while trying to maintain a sense of normalcy; and handle financial struggles.
The combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the aromatase inhibitor, exemestane, is approved for use in postmenopausal women with HR+, HER2– ABC after failure on letrozole or anastrozole treatment.
This study describes the nurse perspective on the importance of biomarker testing for patients with metastatic non–small cell lung cancer (NSCLC) and identifies best practices and process gaps.
Endocrine therapy is recommended for patients with hormone receptor–positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease).
Of the 1.6 million individuals annually diagnosed with cancer, 522,166 received chemoradation, with 234,975 developing toxic mucositis and 20% dying within 5 years due largely to mucositis-mediated unplanned treatment breaks.
Endometrial and ovarian cancers are the sixth and seventh most common cancers in women worldwide.
Symptoms that patients with cancer experience, either due to their illness or as a result of cancer treatment, are known to diminish their health-related quality of life.
Significantly improved outcomes with D+T vs BRAF inhibitor (BRAFi) monotherapy have been demonstrated in phase 3 BRAF V600E/K–mutant melanoma trials (COMBI-d [NCT01584648]; COMBI-v [NCT01597908]), supporting use of D+T as a treatment for this disease.
John C. Byrd, MD, Alvina D. Chu, MD, Steven Coutre, MD, Tony Lin, PharmD, Ying Luan, PhD, Fan Ny, NP, Jillian Settlemire, RN
Ibrutinib, a B-cell receptor pathway inhibitor, is approved in the United States for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for treatment without chemotherapy.
Chimeric antigen receptor (CAR) T cells are engineered from a patient’s own immune cells to redirect them to attack tumor cells.
Breast cancer occurs predominantly in older, postmenopausal women (>50 years), although the incidence of ABC in younger, premenopausal women is increasing.
Results 1 - 42 of 42
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512